GlassScriptPhysician profile
David A Elliott
NPI 1811986581
$7,540.89
in general payments reported to CMS, 2019-2025
29 companies · $1,538 in 2025
The $1,538 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,363 · 2020: $599 · 2021: $1,187 · 2022: $1,074 · 2023: $557 · 2024: $1,223 · 2025: $1,538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,318.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,695.23 | 2019-2025 | |
| Janssen Biotech, INC. | $1,340.88 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $739.13 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $468.96 | 2019-2025 | Entyvio, Gattex |
| Gilead Sciences, INC. | $430.25 | 2019-2024 | Epclusa |
| Pfizer INC. | $391.49 | 2021-2025 | |
| Braintree Laboratories, INC. | $347.46 | 2019-2025 | Sutab, Suflave |
| Celgene Corporation | $294.66 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $281.19 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $199.78 | 2024-2025 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $178.45 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $150.06 | 2024-2025 | Voquezna |
| Intuitive Surgical, INC. | $132.32 | 2019 | |
| Ferring Pharmaceuticals INC. | $106.57 | 2019-2023 | Rebyota |
| Janssen Scientific Affairs, LLC | $102.94 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $81.64 | 2021-2023 | Conmed Eus, Conmed Biliary |
| Boston Scientific Corporation | $75.92 | 2022-2024 | Exalt Model D |
| Intercept Pharmaceuticals, INC. | $75.62 | 2020-2021 | |
| Redhill Biopharma INC. | $69.23 | 2020-2021 | |
| Novo Nordisk INC | $61.51 | 2025 | Wegovy |
| Allergan, INC. | $53.36 | 2019-2020 | |
| Ardelyx, INC. | $51.36 | 2024-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $49.82 | 2019-2023 | Linzess |
| Olympus America INC. | $46.42 | 2025 | Endoclot Phs |
| Vivus LLC | $34.55 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $25.26 | 2023 | Dupixent |
| Shire North American Group INC | $21.97 | 2019 | |
| Fresenius Kabi USA, LLC | $19.80 | 2024 | Idacio |
| Pacira Pharmaceuticals Incorporated | $15.06 | 2024 | Exparel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Elliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.